Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 in Lupus Nephritis
NCT07044115Phase 2Active, not recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Nov 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Bejescin in lupus nephritis (LN), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Started Nov 2021; status: active, not recruiting.
02
Drugs
Bejescin
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07044115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044115.